XRAY

Analyst Note: XRAY (DENTSPLY SIRONA Inc.)

Date: 2026-06-20 Current Price: $10.33

1. Structural Readiness

• State: Avoid
• Conservative Entry: — (Awaiting confirmed breakout)
• Aggressive/Pre-Breakout Entry: — (Not actionable on forming structure alone)
• Current Price: $10.33
• Extension: — (Price is not currently extended above a breakout level as no breakout has occurred)

2. Thesis Layer

This is a TACTICAL, setup-led name. As of 2026-06-20, there is NO named macro or secular thesis attached to this setup in the current data. The investment case must be judged strictly on the quality of the structural setup (the forming coil) and the immediate business fundamentals provided in the evidence. No external narrative or "story" should be invented to support the position; the conviction rests entirely on the execution of the restructuring and the stability of the underlying market as reported by management.

3. Business Overview

DENTSPLY SIRONA Inc. is the world's largest diversified manufacturer of professional dental products and technologies, operating with a 139-year history. As of the 2026-02-26 filing, the company conducts business through four reportable segments:

• Connected Technology Solutions
• Essential Dental Solutions
• Orthodontic and Implant Solutions
• Wellspect Healthcare

Financial & Operational Context (as of 2026-06-20):

• Revenue Guidance: Management is maintaining its 2026 outlook for net sales of $3.5 billion to $3.6 billion.
• Recent Performance: First quarter 2026 revenue was $880 million, representing a 0.1% as-reported sales increase over the prior quarter.
• Profitability Outlook: Adjusted EPS is expected in the range of $1.40 to $1.50 for 2026.
• Restructuring: A restructuring program is on track to deliver approximately $120 million in annual savings. Management expects benefits to build through 2026, becoming "more meaningful in the second half of the year."
• Strategic Partnerships: An expanded agreement with Atlanta Dental Supply was signed, adding the connected technology solutions portfolio effective August 1, 2026.
• Investment Strategy: The company plans to increase annual R&D investment to approximately 5% of net sales beginning in 2026 (up from a historical average of ~4%). This includes further development of the DS Core platform.
• Product Innovation: In 2025, the company introduced the CEREC Primemill Lite, a budget-friendly format for bridges and veneers.
• Workforce: Approximately 14,000 employees globally (including ~3,000 in the US) as of December 31, 2025.

4. Archetype and Conviction

• Archetype: Structurally Broken (Source: layer_b).
• *Rationale:* The company is currently in a transition phase characterized by a restructuring program aimed at cost reduction ($120M savings) and a shift in capital allocation (increasing R&D to 5% of sales). The "broken" nature is reflected in the suppressed stock price ($10.33) relative to the guidance, suggesting the market is pricing in the near-term drag of restructuring costs and external pressures before the benefits materialize.
• Valuation & Fundamentals:
• The stock trades at a low multiple relative to the 2026 EPS guidance of $1.40–$1.50 (implied forward P/E of ~6.9x–7.4x at $10.33).
• The business model is defensive, supported by an aging demographic shift and stable underlying market demand, though near-term performance is affected by external pressures.
• Conviction Stack:
• Thesis Strength: Low (No named macro thesis; purely tactical).
• Evidence Quality: High (Clear management guidance on sales, EPS, and savings; specific product and partnership announcements).
• Structural Quality: Moderate (ATR is 4.8%, which falls in the "high" canonical bucket, indicating elevated volatility. This is within the 4–6% "sweet spot" for structural quality, suggesting the stock is not "dead" but active).
• Setup Readiness: Partial (Forming coil). The structure is in place, but the breakout has not fired.
• Rerating Potential: Dependent on the realization of the $120M savings and the successful ramp-up of the 5% R&D investment.

5. Invalidations, Strengtheners, and Gaps

• Gaps in Evidence:
• Q2-Q4 Specifics: While management expects items to drive performance from Q2 through Q4, specific quarterly breakdowns for the remainder of 2026 are not detailed in the provided evidence.
• Competitive Landscape: No specific data on market share gains or losses relative to competitors is provided in the evidence.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management maintaining $3.5B-$3.6B sales guidance and $1.40-$1.50 EPS range for 2026; Restructuring program on track for $120M annual savings with benefits building in H2 2026; ATR of 4.8% indicates active volatility within the structural sweet spot. Key risks: Near-term performance still affected by external pressures and timing of investments; Restructuring savings may not materialize as quickly as expected; Stock price remains in a forming state with no confirmed breakout signal. Sizing hint: Position size should be minimal or zero until a confirmed breakout occurs; do not size based on the forming structure alone. Expected path: Management expects the restructuring benefits to become more meaningful in the second half of 2026, potentially driving a re-rating if the structural breakout confirms. Expected horizon: Second half of 2026, contingent on the realization of savings and a confirmed technical breakout.